presented to its investors. ACELYRIN, INC. is a late-stage clinical biopharmaceutical company that focuses on developing transformative medicines in immunology, with a lead program targeting thyroid ...
ACELYRIN previously announced that enrollment in a Phase 2b/3 trial evaluating 160mg of izokibep administered weekly as a treatment for non-infectious, non-interior uveitis had been completed in May ...